Viral Vector Therapies at scale

Today’s challenges and future opportunity

The past five years have seen viral-vector-based gene therapies become a reality. To date, eight therapies have been approved by the US Food and Drug Administration (FDA) across three different types of viral vectors: adeno-associated virus (AAV), lentivirus, and herpes simplex virus.With 25 viral-vector therapeutics in late-stage development and another 120 in Phase II trials as of February 2022, the number of approved therapies is only expected to grow.

Know more